A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice.
arsenic
chronic GvHD
copper
fibrosis
reactive oxygen species
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
04
2022
accepted:
06
07
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
30
8
2022
Statut:
epublish
Résumé
Graft-versus Host Disease (GvHD) is a major complication of hematopoietic stem cell transplant. GvHD is characterized by the chronic activation of immune cells leading to the development of systemic inflammation, autoimmunity, fibrosis and eventually death. Arsenic trioxide (ATO) is a therapeutic agent under clinical trial for the treatment of patients with systemic lupus erythematosus (SLE) and chronic GvHD (cGvHD). This therapy is admittedly rather safe although adverse effects can occur and may necessitate short interruptions of the treatment. The aim of this study was to combine ATO with a divalent cation, to generate a Fenton or Fenton-like reaction in order to potentiate the deletion of activated immune cells through the reactive oxygen species (ROS)-mediated effects of ATO in a mouse model, and thereby enabling the use of lower and safer ATO concentrations to treat patients with cGvHD.
Identifiants
pubmed: 36016953
doi: 10.3389/fimmu.2022.917739
pmc: PMC9395715
doi:
Substances chimiques
Arsenicals
0
Cations
0
Oxides
0
Arsenic Trioxide
S7V92P67HO
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
917739Informations de copyright
Copyright © 2022 Chêne, Jeljeli, Rongvaux-Gaïda, Thomas, Rieger, Batteux and Nicco.
Déclaration de conflit d'intérêts
FR and FB are listed inventors for an early patent application family (designation) relative to the synergic use of arsenic salts and metallic ions for the treatment of autoimmune diseases. DR-G and FR are currently employees of MEDSENIC SAS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biol Blood Marrow Transplant. 2018 Aug;24(8):1629-1642
pubmed: 29548831
J Immunol. 2002 Mar 15;168(6):3088-98
pubmed: 11884483
Arthritis Res Ther. 2021 Mar 3;23(1):70
pubmed: 33658052
Cell Death Dis. 2018 Mar 14;9(3):408
pubmed: 29540672
J Adv Res. 2015 May;6(3):449-58
pubmed: 26257943
Blood. 2017 Feb 23;129(8):927-933
pubmed: 27940475
Mol Cancer. 2019 Mar 30;18(1):54
pubmed: 30925928
Biol Blood Marrow Transplant. 2015 Jan;21(1):16-23
pubmed: 25452031
Blood. 2001 Jul 15;98(2):266-71
pubmed: 11435292
Immunology. 2003 Jul;109(3):440-9
pubmed: 12807491
Int J Toxicol. 2006 Sep-Oct;25(5):319-31
pubmed: 16940004
Innate Immun. 2011 Aug;17(4):365-74
pubmed: 20693187
Am J Hematol. 2012 Dec;87(12):1057-64
pubmed: 22965904
J Clin Invest. 2014 Oct;124(10):4266-80
pubmed: 25157821
EBioMedicine. 2019 Mar;41:584-596
pubmed: 30772305
Am J Pathol. 2009 Jul;175(1):225-34
pubmed: 19498006
Toxins (Basel). 2019 May 15;11(5):
pubmed: 31096598
Br J Haematol. 2019 Sep;186(5):e145-e148
pubmed: 31135953
Blood. 2017 May 4;129(18):2570-2580
pubmed: 28254742
Blood. 2004 Dec 1;104(12):3501-6
pubmed: 15292060
Blood. 1997 May 1;89(9):3354-60
pubmed: 9129042
J Toxicol. 2011;2011:431287
pubmed: 22174709
N Engl J Med. 2017 Dec 28;377(26):2565-2579
pubmed: 29281578
Blood. 2016 Feb 4;127(5):646-57
pubmed: 26670634
J Exp Med. 1997 Jan 6;185(1):71-9
pubmed: 8996243
Front Immunol. 2019 Mar 06;10:334
pubmed: 30894856
Blood. 2017 Jan 5;129(1):30-37
pubmed: 27821503
Molecules. 2018 Nov 29;23(12):
pubmed: 30501042
Leuk Res. 2011 Sep;35(9):1170-7
pubmed: 21774985
Front Immunol. 2021 Aug 03;12:670776
pubmed: 34413847
Toxicol Lett. 1995 Dec;82-83:969-74
pubmed: 8597169
J Immunol. 2012 May 15;188(10):5142-9
pubmed: 22491256
Nat Med. 2014 Jun;20(6):648-54
pubmed: 24836575
J Invest Dermatol. 2016 Nov;136(11):2158-2167
pubmed: 27424318
J Biochem Mol Toxicol. 2008 Mar-Apr;22(2):85-92
pubmed: 18418892
Transplantation. 2015 Sep;99(9):1796-806
pubmed: 25919768
J Neurosci Res. 2018 Feb;96(2):194-206
pubmed: 28419510
Blood. 2009 Dec 3;114(24):4919-27
pubmed: 19749094
Toxicol Sci. 2008 Dec;106(2):350-63
pubmed: 18728046
Mol Cancer Ther. 2003 Aug;2(8):711-9
pubmed: 12939460
Chemistry. 2021 Oct 7;27(56):13953-13960
pubmed: 34196066
Aging (Albany NY). 2020 Jul 4;12(17):16867-16886
pubmed: 32952128
Cardiovasc Toxicol. 2002;2(1):63-73
pubmed: 12189281
Oncologist. 2003;8(2):132-40
pubmed: 12697938
Int J Environ Res Public Health. 2006 Jun;3(2):136-40
pubmed: 16823087
Respir Res. 2014 Apr 24;15:51
pubmed: 24762191
Toxicol Appl Pharmacol. 2013 Jan 15;266(2):204-13
pubmed: 23164666
J Vis Exp. 2012 Feb 01;(60):
pubmed: 22331082
Sci China Life Sci. 2020 Nov;63(11):1744-1754
pubmed: 32382983
Haematologica. 2018 Sep;103(9):1535-1541
pubmed: 29858386
Chem Biol Interact. 2021 Aug 1;344:109501
pubmed: 33974898
Biometals. 2014 Dec;27(6):1303-22
pubmed: 25216733